GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kimia Biosciences Ltd (BOM:530313) » Definitions » Current Deferred Revenue

Kimia Biosciences (BOM:530313) Current Deferred Revenue : ₹0.00 Mil (As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Kimia Biosciences Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Kimia Biosciences's current deferred revenue for the quarter that ended in . 20 was ₹0.00 Mil.

Kimia Biosciences Current Deferred Revenue Historical Data

The historical data trend for Kimia Biosciences's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kimia Biosciences Current Deferred Revenue Chart

Kimia Biosciences Annual Data
Trend
Current Deferred Revenue

Kimia Biosciences Semi-Annual Data
Current Deferred Revenue

Kimia Biosciences Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Kimia Biosciences's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kimia Biosciences (BOM:530313) Business Description

Traded in Other Exchanges
N/A
Address
Netaji Subhash Place, 974, 9th Floor, Aggarwal Millenium Tower-II, Pitampura, New Delhi, IND, 110 034
Kimia Biosciences Ltd is a company engaged in the manufacturing of bulk drugs. Some of the company's products include Azelnidipine, Deflazacort, Oxaceprol, Seratodast, and Tretinoin among others. Its only operating segment being Pharmaceuticals.

Kimia Biosciences (BOM:530313) Headlines

No Headlines